Scott Blumberg Sells 652 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CFO Scott Blumberg sold 652 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $16,300.00. Following the transaction, the chief financial officer directly owned 146,600 shares of the company’s stock, valued at $3,665,000. The trade was a 0.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Scott Blumberg also recently made the following trade(s):

• On Friday, August 21st, Scott Blumberg sold 1,521 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $36,534.42.
• On Wednesday, August 19th, Scott Blumberg sold 33,512 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $838,805.36.
• On Tuesday, August 18th, Scott Blumberg sold 990 shares of CeriBell stock. The shares were sold at an average price of $25.00, for a total value of $24,750.00.

CeriBell Trading Up 0.6%

CeriBell stock opened at $24.72 on Friday. The stock has a 50-day moving average price of $20.67 and a 200 day moving average price of $19.49. CeriBell, Inc. has a 52 week low of $10.85 and a 52 week high of $25.33. The stock has a market cap of $948.75 million, a PE ratio of -14.05 and a beta of 0.95. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last released its earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Equities research analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CeriBell

A number of institutional investors have recently bought and sold shares of CBLL. Caitong International Asset Management Co. Ltd raised its stake in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after purchasing an additional 1,231 shares during the period. Strs Ohio purchased a new stake in shares of CeriBell during the 1st quarter valued at $27,000. CWM LLC increased its holdings in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the last quarter. Finally, Legal & General Group Plc purchased a new position in shares of CeriBell in the 2nd quarter worth $53,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CBLL. Barclays upgraded shares of CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Canaccord Genuity Group increased their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. BTIG Research raised their price objective on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research report on Thursday. Finally, Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.40.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.